Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome (Q35827704)

10 August 2017

Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome (English)

1 reference

10 August 2017

1 reference

György Paragh

1 reference

10 August 2017

Ildikó Seres

1 reference

10 August 2017

Mariann Harangi

1 reference

10 August 2017

Annamária Erdei

1 reference

10 August 2017

Mária Audikovszky

1 reference

10 August 2017

Lóránd Debreczeni

1 reference

10 August 2017

Anna Kovácsay

1 reference

10 August 2017

László Illyés

1 reference

10 August 2017

Gyula Pados

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

British Journal of Clinical Pharmacology

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

694-701

1 reference

The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Lipid abnormalities in insulin resistant states

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Development of approximate formula for LDL-chol, LDL-apo B and LDL-chol/LDL-apo B as indices of hyperapobetalipoproteinemia and small dense LDL.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Paraoxonase Polymorphism (Gln192-Arg) Is Associated with Coronary Heart Disease in Japanese Noninsulin-Dependent Diabetes Mellitus

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Paraoxonase genotypes, lipoprotein lipase activity, and HDL.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

HDL, its enzymes and its potential to influence lipid peroxidation.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Plasma Triglyceride and Fatty Acid Metabolism in Diabetes mellitus

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

The triglyceride issue: a view from Framingham

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Fibric acids: effects on lipids and lipoprotein metabolism

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Lipoprotein metabolism in diabetes mellitus

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Review of European clinical experience with fenofibrate

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Antioxidant paraoxonase 1 activity in the metabolic syndrome

11 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02565.X

The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic le

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02565.X

Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02565.X

Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02565.X

Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02565.X

Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02565.X

Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02565.X

The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

The polymorphic paraoxonase/arylesterase isozymes of human serum.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885110

Maturity onset diabetes mellitus: response to intensive dietary management

24 September 2018

1 reference

12 December 2020

Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein

1 reference

12 December 2020

Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus

1 reference

12 December 2020

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study

1 reference

12 December 2020

Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study

1 reference

12 December 2020

Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes

1 reference

12 December 2020

Serum Paraoxonase Activity, Concentration, and Phenotype Distribution in Diabetes Mellitus and Its Relationship to Serum Lipids and Lipoproteins

1 reference

12 December 2020

Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate

1 reference

12 December 2020

Paraoxonase producing PON1 gene M/L55 polymorphism is related to autopsy-verified artery-wall atherosclerosis

1 reference

12 December 2020

10.1111/J.1365-2125.2006.02565.X

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

16722831

1 reference